JDD December Editor’s Picks: A Spotlight on Dermatology’s Latest Innovations
As 2024 comes to a close, the Journal of Drugs in Dermatology delivers a stellar lineup of research, reviews, and insights to inform your practice and inspire your curiosity. This month's Editor's Picks feature cutting-edge studies and expert commentary on a range of topics, from advanced acne treatments to groundbreaking leadership initiatives in dermatology.
Laser and Energy Treatments for Ac …
As 2024 comes to a close, the Journal of Drugs in Dermatology delivers a stellar lineup of research, reviews, and insights to inform your practice and inspire your curiosity. This month's Editor's Picks feature cutting-edge studies and expert commentary on a range of topics, from advanced acne treatments to groundbreaking leadership initiatives in dermatology.
Laser and Energy Treatments for Ac … Continue reading "JDD December Editor’s Picks: A Spotlight on Dermatology’s Latest Innovations"
Ketoconazole is an imidazole antifungal that was initially FDA-approved in an oral formulation for the treatment of systemic fungal infections. While oral ketoconazole has largely fallen out of use due to safety concerns, including hepatotoxicity, endocrine dysregulation, and drug interactions, topical ketoconazole has proven to be a safe and effective treatment for superficial fungal infections. … 
Calcipotriene is a synthetic Vitamin D3 analogue with various functions, including promoting cellular differentiation and reducing inflammatory cytokines. The unique mechanism of action of calcipotriene has expanded its utility beyond psoriasis to off-label uses for other dermatologic conditions. Calcipotriene is well tolerated and can be used in conjunction with other treatment modalities. We con … 
Pentoxifylline is a methyl-xanthine derivative traditionally used to treat symptoms of peripheral vascular disease and has emerged as a valuable therapeutic agent in dermatology for its anti-inflammatory and immunomodulatory properties. We continue our series, Therapeutic Cheat Sheet, with a closer look at pentoxifylline, which is FDA-approved for the treatment of intermittent claudication and is … 
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre … 